메뉴 건너뛰기




Volumn 19, Issue 6, 2017, Pages

Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician

Author keywords

Biologics; Biosimilars; Clinical trials; Real world data; Switching

Indexed keywords

ADALIMUMAB; ADALIMUMAB ATTO; BIOSIMILAR AGENT; ETANERCEPT; ETANERCEPT SZZS; INFLIXIMAB; INFLIXIMAB DYYB; RITUXIMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; DERMATOLOGICAL AGENT; GASTROINTESTINAL AGENT;

EID: 85021188038     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-017-0658-4     Document Type: Review
Times cited : (82)

References (119)
  • 1
    • 84966283006 scopus 로고    scopus 로고
    • Accessed 31 Mar 2016
    • European Medicines Agency. Guideline on similar biological medicinal products. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf. Accessed 31 Mar 2016.
    • (2014) Guideline on similar biological medicinal products
  • 2
    • 84942234810 scopus 로고    scopus 로고
    • Scientific considerations in demonstrating biosimilarity to a reference product
    • United States Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry. 2015. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/UCM291128.pdf. Accessed 31 Mar 2016.
    • (2015) Guidance for industry
    • Food, U.S.1    Administration, D.2
  • 3
  • 4
    • 84863435547 scopus 로고    scopus 로고
    • The advent of biosimilar therapies in rheumatology–“O Brave New World
    • Scheinberg MA, Kay J. The advent of biosimilar therapies in rheumatology–“O Brave New World”. Nat Rev Rheumatol. 2012;8:430–6.
    • (2012) Nat Rev Rheumatol , vol.8 , pp. 430-436
    • Scheinberg, M.A.1    Kay, J.2
  • 5
    • 84964262382 scopus 로고    scopus 로고
    • Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology
    • COI: 1:CAS:528:DC%2BC28XjslOqtrc%3D, PID: 26920148
    • Mysler E, Pineda C, Horiuchi T, Singh E, Mahgoub E, Coindreau J, et al. Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology. Rheumatol Int. 2016;36:613–25. doi:10.1007/s00296-016-3444-0.
    • (2016) Rheumatol Int , vol.36 , pp. 613-625
    • Mysler, E.1    Pineda, C.2    Horiuchi, T.3    Singh, E.4    Mahgoub, E.5    Coindreau, J.6
  • 8
    • 84948714780 scopus 로고    scopus 로고
    • Biosimilars in rheumatology: current perspectives and lessons learnt
    • PID: 26282080
    • Dorner T, Kay J. Biosimilars in rheumatology: current perspectives and lessons learnt. Nat Rev Rheumatol. 2015;11:713–24. doi:10.1038/nrrheum.2015.110.
    • (2015) Nat Rev Rheumatol , vol.11 , pp. 713-724
    • Dorner, T.1    Kay, J.2
  • 9
    • 84969996341 scopus 로고    scopus 로고
    • Interchangeability. An insurmountable fifth hurdle?
    • Ebbers HC, Chamberlain P. Interchangeability. An insurmountable fifth hurdle? GaBI J. 2014;3:88–93. doi:10.5639/gabij.2014.0302.022.
    • (2014) GaBI J , vol.3 , pp. 88-93
    • Ebbers, H.C.1    Chamberlain, P.2
  • 10
    • 84872423673 scopus 로고    scopus 로고
    • On the interchangeability of biologic drug products
    • PID: 22911936
    • Endrenyi L, Chang C, Chow SC, Tothfalusi L. On the interchangeability of biologic drug products. Stat Med. 2013;32:434–41. doi:10.1002/sim.5569.
    • (2013) Stat Med , vol.32 , pp. 434-441
    • Endrenyi, L.1    Chang, C.2    Chow, S.C.3    Tothfalusi, L.4
  • 11
    • 84944325199 scopus 로고    scopus 로고
    • Clinical trial development for biosimilars
    • PID: 26058550
    • Alten R, Cronstein BN. Clinical trial development for biosimilars. Semin Arthritis Rheum. 2015;44:S2–8. doi:10.1016/j.semarthrit.2015.04.002.
    • (2015) Semin Arthritis Rheum , vol.44 , pp. S2-S8
    • Alten, R.1    Cronstein, B.N.2
  • 12
  • 14
    • 0008348082 scopus 로고    scopus 로고
    • Accessed 31 Oct
    • European Medicines Agency. European public assessment reports (biosimilars). http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=WC0b01ac058001d124&searchTab=searchByAuthType&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keyword=Enter+keywords&searchType=name&taxonomyPath=&treeNumber=&searchGenericType=biosimilars&genericsKeywordSearch=Submit. Accessed 31 Oct 2016.
    • (2016) European public assessment reports (biosimilars)
  • 15
    • 85021229415 scopus 로고    scopus 로고
    • Accessed 31 Oct 2016
    • United States Food and Drug Administration. Center for drug evaluation and research list of licensed biological products. 2016. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/UCM439049.pdf. Accessed 31 Oct 2016.
    • (2016) Center for drug evaluation and research list of licensed biological products
  • 19
    • 85021227371 scopus 로고    scopus 로고
    • Accessed 28 Feb
    • European Medicines Agency. Human medicines: pending EC decisions: Amgevita. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004212/smops/Positive/human_smop_001091.jsp&mid=WC0b01ac058001d127&source=homeMedSearch&category=human. Accessed 28 Feb 2017.
    • (2017) Human medicines: pending EC decisions: Amgevita
  • 20
    • 85021227371 scopus 로고    scopus 로고
    • Accessed 28 Feb
    • European Medicines Agency. Human medicines: pending EC decisions: Solymbic. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004373/smops/Positive/human_smop_001092.jsp&mid=WC0b01ac058001d127&source=homeMedSearch&category=human. Accessed 28 Feb 2017.
    • (2017) Human medicines: pending EC decisions: Solymbic
  • 21
    • 85021202207 scopus 로고    scopus 로고
    • SB5, an adalimumab biosimilar referencing Humira®
    • Biogen. SB5, an adalimumab biosimilar referencing Humira®, accepted for review by European Medicines Agency. 2016. http://media.biogen.com/press-release/biosimilars/sb5-adalimumab-biosimilar-referencing-humira-accepted-review-european-medi. Accessed 31 Oct 2016.
    • (2016) accepted for review by European Medicines Agency
  • 22
    • 85021220682 scopus 로고    scopus 로고
    • Accessed 31 Oct 2016
    • Generics and Biosimilars Initiative. Celltrion submits rituximab biosimilar application to EMA. 2015. http://www.gabionline.net/Biosimilars/News/Celltrion-submits-rituximab-biosimilar-application-to-EMA. Accessed 31 Oct 2016. doi:10.3402/ijch.v74.27284.
    • (2015) Celltrion submits rituximab biosimilar application to EMA
  • 24
    • 85021232355 scopus 로고    scopus 로고
    • Efficacy and safety of CT-P13 (infliximab biosimilar) over two years in patients with rheumatoid arthritis: comparison between continued CT-P13 and switching from infliximab to CT-P13
    • San Diego, California, USA
    • Yoo DH, Prodanovic N, Jaworski J, Miranda P, Ramiterre E, Lanzon A, et al. Efficacy and safety of CT-P13 (infliximab biosimilar) over two years in patients with rheumatoid arthritis: comparison between continued CT-P13 and switching from infliximab to CT-P13. American College of Rheumatology 2013; San Diego, California, USA: 2013.
    • (2013) American College of Rheumatology , vol.2013
    • Yoo, D.H.1    Prodanovic, N.2    Jaworski, J.3    Miranda, P.4    Ramiterre, E.5    Lanzon, A.6
  • 25
    • 84966417145 scopus 로고    scopus 로고
    • Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study
    • PID: 27130908, This study is the largest study of switching from infliximab to CT-P13 exclusively in patients with rheumatoid arthritis, and specifically compares clinical data before and after switching
    • • Yoo DH, Prodanovic N, Jaworski J, Miranda P, Ramiterre E, Lanzon A, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis. 2017;76:355–63. doi:10.1136/annrheumdis-2015-208786. This study is the largest study of switching from infliximab to CT-P13 exclusively in patients with rheumatoid arthritis, and specifically compares clinical data before and after switching.
    • (2017) Ann Rheum Dis , vol.76 , pp. 355-363
    • Yoo, D.H.1    Prodanovic, N.2    Jaworski, J.3    Miranda, P.4    Ramiterre, E.5    Lanzon, A.6
  • 26
    • 84970012234 scopus 로고    scopus 로고
    • Efficacy and safety of CT-P13 (infliximab biosimilar) over two years in patients with ankylosing spondylitis: comparison between continuing with CT-P13 and switching from infliximab to CT-P13
    • San Diego, California, USA
    • Park W, Miranda P, Brzosko M, Wiland P, Gutierrez-Ureña S, Mikazane H, et al. Efficacy and safety of CT-P13 (infliximab biosimilar) over two years in patients with ankylosing spondylitis: comparison between continuing with CT-P13 and switching from infliximab to CT-P13. American College of Rheumatology 2013; San Diego, California, USA: 2013.
    • (2013) American College of Rheumatology , vol.2013
    • Park, W.1    Miranda, P.2    Brzosko, M.3    Wiland, P.4    Gutierrez-Ureña, S.5    Mikazane, H.6
  • 27
    • 84965014483 scopus 로고    scopus 로고
    • Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study
    • PID: 27117698, This study is the largest study of switching from infliximab to CT-P13 exclusively in patients with ankylosing spondylitis, and specifically compares clinical data before and after switching
    • • Park W, Yoo DH, Miranda P, Brzosko M, Wiland P, Gutierrez-Ureña S, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis. 2017;76:346–54. doi:10.1136/annrheumdis-2015-208783. This study is the largest study of switching from infliximab to CT-P13 exclusively in patients with ankylosing spondylitis, and specifically compares clinical data before and after switching.
    • (2017) Ann Rheum Dis , vol.76 , pp. 346-354
    • Park, W.1    Yoo, D.H.2    Miranda, P.3    Brzosko, M.4    Wiland, P.5    Gutierrez-Ureña, S.6
  • 28
    • 84984714652 scopus 로고    scopus 로고
    • Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab
    • Tanaka Y, Yamanaka H, Takeuchi T, Inoue M, Saito K, Saeki Y, et al. Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab. Mod Rheumatol. 2017;27:237-45.
    • (2017) Mod Rheumatol , vol.27 , pp. 237-245
    • Tanaka, Y.1    Yamanaka, H.2    Takeuchi, T.3    Inoue, M.4    Saito, K.5    Saeki, Y.6
  • 29
    • 85021197245 scopus 로고    scopus 로고
    • A descriptive analysis of real-world treatment patterns in a Turkish rheumatology population that continued innovator infliximab (Remicade) therapy or switched to biosimilar infliximab
    • Washington DC, USA: Arthritis Rheumatol, Accessed 17 May 2017
    • Yazici Y, Xie L, Ogbomo A, Parenti D, Goyal K, Teeple A, et al. A descriptive analysis of real-world treatment patterns in a Turkish rheumatology population that continued innovator infliximab (Remicade) therapy or switched to biosimilar infliximab. American College of Rheumatology; 2016 Washington DC, USA: Arthritis Rheumatol. 2016;68 (suppl10). http://acrabstracts.org/abstract/a-descriptive-analysis-of-real-world-treatment-patterns-in-a-turkish-rheumatology-population-that-continued-innovator-infliximab-remicade-therapy-or-switched-to-biosimilar-infliximab/ Accessed 17 May 2017.
    • (2016) American College of Rheumatology , vol.68
    • Yazici, Y.1    Xie, L.2    Ogbomo, A.3    Parenti, D.4    Goyal, K.5    Teeple, A.6
  • 31
    • 85021195497 scopus 로고    scopus 로고
    • Non-medical switch from originator to biosimilar infliximab in patients with inflammatory arthritis: impact on s-infliximab and antidrug antibodies. Results from the Danish Rheumatological Biobank and the DANBIO registry
    • The DANBIO registry analysis is the largest real-world study of the effects of switching from infliximab to CT-P13 in patients with rheumatic disease to date. This publication provides important early immunogenicity data on the effect of switching
    • • Glintborg B, Kringelbach T, Høgdall E, Sørensen IJ, Jensen DV, Loft AG, et al. Non-medical switch from originator to biosimilar infliximab in patients with inflammatory arthritis: impact on s-infliximab and antidrug antibodies. Results from the Danish Rheumatological Biobank and the DANBIO registry. Scandinavian Congress of Rheumatology; Reykjavik: 2016. The DANBIO registry analysis is the largest real-world study of the effects of switching from infliximab to CT-P13 in patients with rheumatic disease to date. This publication provides important early immunogenicity data on the effect of switching.
    • (2016) Scandinavian Congress of Rheumatology; Reykjavik
    • Glintborg, B.1    Kringelbach, T.2    Høgdall, E.3    Sørensen, I.J.4    Jensen, D.V.5    Loft, A.G.6
  • 32
    • 85021246962 scopus 로고    scopus 로고
    • Non-medical switch from originator to biosimilar infliximab among patients with inflammatory rheumatic disease–impact on s-infliximab and anti-drug antibodies. Results from the National Danish Rheumatologic Biobank and the DANBIO registry
    • London, UK; Ann Rheum Dis: 2016. The DANBIO registry analysis is the largest real-world study of the effects of switching from infliximab to CT-P13 in patients with rheumatic disease to date. This publication provides important early immunogenicity data on the effects of switching
    • • Glintborg B, Kringelbach T, Høgdall E, Sørensen IJ, Jensen DV, Loft AG, et al. Non-medical switch from originator to biosimilar infliximab among patients with inflammatory rheumatic disease–impact on s-infliximab and anti-drug antibodies. Results from the National Danish Rheumatologic Biobank and the DANBIO registry. European League Against Rheumatism 2016; London, UK; Ann Rheum Dis: 2016. The DANBIO registry analysis is the largest real-world study of the effects of switching from infliximab to CT-P13 in patients with rheumatic disease to date. This publication provides important early immunogenicity data on the effects of switching.
    • (2016) European League Against Rheumatism
    • Glintborg, B.1    Kringelbach, T.2    Høgdall, E.3    Sørensen, I.J.4    Jensen, D.V.5    Loft, A.G.6
  • 33
    • 85021222436 scopus 로고    scopus 로고
    • A nationwide non-medical switch from originator to biosimilar infliximab in patients with inflammatory arthritis. Eleven months’ clinical outcomes from the Danbio Registry
    • Washington DC, USA: 2016. The DANBIO registry analysis is the largest real-world study of the effects of switching from infliximab to CT-P13 in patients with rheumatic disease to date. This publication provides important longer-term clinical data on the efficacy and safety of switching
    • • Glintborg B, Sørensen IJ, Jensen DV, Krogh NS, Loft AG, Espesen J, et al. A nationwide non-medical switch from originator to biosimilar infliximab in patients with inflammatory arthritis. Eleven months’ clinical outcomes from the Danbio Registry. American College of Rheumatology 2016; Washington DC, USA: 2016. The DANBIO registry analysis is the largest real-world study of the effects of switching from infliximab to CT-P13 in patients with rheumatic disease to date. This publication provides important longer-term clinical data on the efficacy and safety of switching.
    • (2016) American College of Rheumatology
    • Glintborg, B.1    Sørensen, I.J.2    Jensen, D.V.3    Krogh, N.S.4    Loft, A.G.5    Espesen, J.6
  • 34
    • 85021192993 scopus 로고    scopus 로고
    • Non-medical switch from originator to biosimilar infliximab in patients with inflammatory arthritis—impact on s-infliximab and antidrug-antibodies. Results from the Danish Rheumatologic Biobank and the Danbio Registry
    • Washington DC, USA: 2016. The DANBIO registry analysis is the largest real-world study of the effects of switching from infliximab to CT-P13 in patients with rheumatic disease to date. This publication provides important longer-term immunogenicity data on the effects of switching
    • • Glintborg B, Kringelbach TM, Høgdall E, Sørensen IJ, Jensen DV, Loft AG, et al. Non-medical switch from originator to biosimilar infliximab in patients with inflammatory arthritis—impact on s-infliximab and antidrug-antibodies. Results from the Danish Rheumatologic Biobank and the Danbio Registry. American College of Rheumatology 2016; Washington DC, USA: 2016. The DANBIO registry analysis is the largest real-world study of the effects of switching from infliximab to CT-P13 in patients with rheumatic disease to date. This publication provides important longer-term immunogenicity data on the effects of switching.
    • (2016) American College of Rheumatology
    • Glintborg, B.1    Kringelbach, T.M.2    Høgdall, E.3    Sørensen, I.J.4    Jensen, D.V.5    Loft, A.G.6
  • 35
    • 85026616778 scopus 로고    scopus 로고
    • Switching to biosimilar infliximab: real-world data from the Southampton biologic therapies review service
    • Annual Meeting; Glasgow, UK; Rheumatology (Oxford
    • Holroyd C, Parker L, Bennett S, Zarroug J, Underhill C, Davidson B, et al. Switching to biosimilar infliximab: real-world data from the Southampton biologic therapies review service. British Society for Rheumatology 2016 Annual Meeting; Glasgow, UK; Rheumatology (Oxford): 2016. doi:10.1093/rheumatology/kew121.003.
    • (2016) British Society for Rheumatology , vol.2016
    • Holroyd, C.1    Parker, L.2    Bennett, S.3    Zarroug, J.4    Underhill, C.5    Davidson, B.6
  • 36
    • 84979496968 scopus 로고    scopus 로고
    • Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study
    • Benucci M, Gobbi FL, Bandinelli F, Damiani A, Infantino M, Grossi V, et al. Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study. Immunol Res. 2016:1–4. doi:10.1007/s12026-016-8843-5.
    • (2016) Immunol Res , pp. 1-4
    • Benucci, M.1    Gobbi, F.L.2    Bandinelli, F.3    Damiani, A.4    Infantino, M.5    Grossi, V.6
  • 37
    • 85021240324 scopus 로고    scopus 로고
    • Safety and efficacy of switching from innovator to biosimilar infliximab in patients affected by spondyloarthritis. A 6-month observational study
    • London: UK; Ann Rheum Dis
    • Batticciotto A, Parisi S, Gobbi FL, Antivalle M, Benucci M, Fusaro E, et al. Safety and efficacy of switching from innovator to biosimilar infliximab in patients affected by spondyloarthritis. A 6-month observational study. European League Against Rheumatism 2016; London, UK; Ann Rheum Dis: 2016. doi:10.1136/annrheumdis-2016-eular.5115.
    • (2016) European League Against Rheumatism , vol.2016
    • Batticciotto, A.1    Parisi, S.2    Gobbi, F.L.3    Antivalle, M.4    Benucci, M.5    Fusaro, E.6
  • 38
    • 85052688496 scopus 로고    scopus 로고
    • Safety and efficacy of switching from originator to CT-P13 infliximab biosimilar in patients affected by spondyloarthritis. A 6-month observational study
    • Washington DC, USA: Arthritis Rheumatol
    • Batticciotto A, Antivalle M, Gobbi FL, Parisi S, Talotta R, Varisco V, et al. Safety and efficacy of switching from originator to CT-P13 infliximab biosimilar in patients affected by spondyloarthritis. A 6-month observational study. American College of Rheumatology 2016; Washington DC, USA: Arthritis Rheumatol. 2016.
    • (2016) American College of Rheumatology , vol.2016
    • Batticciotto, A.1    Antivalle, M.2    Gobbi, F.L.3    Parisi, S.4    Talotta, R.5    Varisco, V.6
  • 39
    • 85021240270 scopus 로고    scopus 로고
    • Clinical experience with infliximab biosimilar—switch from Remicade
    • Rome, Italy; Ann Rheum Dis
    • Sokka T, Kautiainen H. Clinical experience with infliximab biosimilar—switch from Remicade. European League Against Rheumatism 2015; Rome, Italy; Ann Rheum Dis: 2015. doi:10.1136/annrheumdis-2015-eular.2151.
    • (2015) European League Against Rheumatism , vol.2015
    • Sokka, T.1    Kautiainen, H.2
  • 40
    • 84946601256 scopus 로고    scopus 로고
    • Clinical effectiveness of CT-P13 (infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data
    • COI: 1:CAS:528:DC%2BC2MXhvVSltL3N, PID: 26549204
    • Nikiphorou E, Kautiainen H, Hannonen P, Asikainen J, Kokko A, Rannio T, et al. Clinical effectiveness of CT-P13 (infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15:1677–83. doi:10.1517/14712598.2015.1103733.
    • (2015) Expert Opin Biol Ther , vol.15 , pp. 1677-1683
    • Nikiphorou, E.1    Kautiainen, H.2    Hannonen, P.3    Asikainen, J.4    Kokko, A.5    Rannio, T.6
  • 41
    • 85016146498 scopus 로고    scopus 로고
    • Long term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product
    • London: UK; Ann Rheum Dis
    • Abdalla A, Byrne NE, Conway R, Walsh T, Mannion G, Hanly M, et al. Long term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product. European League Against Rheumatism 2016; London, UK; Ann Rheum Dis: 2016. doi:10.2147/OARRR.S124975.
    • (2016) European League Against Rheumatism , vol.2016
    • Abdalla, A.1    Byrne, N.E.2    Conway, R.3    Walsh, T.4    Mannion, G.5    Hanly, M.6
  • 42
    • 85055728078 scopus 로고    scopus 로고
    • Infliximab biosimilars—switching Remicade to Remsima in routine care: patient acceptability and early outcome data
    • Annual Meeting; Glasgow, UK; Rheumatology (Oxford
    • Malaiya R, McKee Z, Kiely P. Infliximab biosimilars—switching Remicade to Remsima in routine care: patient acceptability and early outcome data. British Society for Rheumatology 2016 Annual Meeting; Glasgow, UK; Rheumatology (Oxford): 2016.
    • (2016) British Society for Rheumatology , vol.2016
    • Malaiya, R.1    McKee, Z.2    Kiely, P.3
  • 43
    • 85021243072 scopus 로고    scopus 로고
    • Clinical and immunogenicity outcomes after switching treatment from innovator infliximab to biosimilar infliximab in rheumatic diseases in daily clinical practice
    • Washington DC: USA
    • Tweehuysen L, van den Bemt BJF, van Ingen IL, de Jong AJL, van der Laan WH, van den Hoogen FHJ, et al. Clinical and immunogenicity outcomes after switching treatment from innovator infliximab to biosimilar infliximab in rheumatic diseases in daily clinical practice. American College of Rheumatology 2016; Washington DC, USA: 2016.
    • (2016) American College of Rheumatology , vol.2016
    • Tweehuysen, L.1    van den Bemt, B.J.F.2    van Ingen, I.L.3    de Jong, A.J.L.4    van der Laan, W.H.5    van den Hoogen, F.H.J.6
  • 45
    • 85021195001 scopus 로고    scopus 로고
    • Outcomes of a managed switching programme changing IBD patients established on originator infliximab to biosimilar infliximab. 11th Congress of the European Crohn’s and Colitis Organisation; Amsterdam
    • Bettey M, Downey L, Underhill C, Callaghan J, Rush M, Ahmed I, et al. Outcomes of a managed switching programme changing IBD patients established on originator infliximab to biosimilar infliximab. 11th Congress of the European Crohn’s and Colitis Organisation; Amsterdam, The Netherlands: 2016.
    • (2016) The Netherlands
    • Bettey, M.1    Downey, L.2    Underhill, C.3    Callaghan, J.4    Rush, M.5    Ahmed, I.6
  • 46
    • 84940081554 scopus 로고    scopus 로고
    • Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study
    • COI: 1:CAS:528:DC%2BC2MXhvFCqtr%2FF, PID: 25974251
    • Jung YS, Park DI, Kim YH, Lee JH, Seo PJ, Cheon JH, et al. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study. J Gastroenterol Hepatol. 2015;30:1705–12. doi:10.1111/jgh.12997.
    • (2015) J Gastroenterol Hepatol , vol.30 , pp. 1705-1712
    • Jung, Y.S.1    Park, D.I.2    Kim, Y.H.3    Lee, J.H.4    Seo, P.J.5    Cheon, J.H.6
  • 48
    • 85021195038 scopus 로고    scopus 로고
    • Elective switching from Remicade® to biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study. 11th Congress of the European Crohn’s and Colitis Organisation; Amsterdam
    • Smits L, Derikx L, Drenth J, de Jong D, van Esch A, Hoentjen F. Elective switching from Remicade® to biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study. 11th Congress of the European Crohn’s and Colitis Organisation; Amsterdam, The Netherlands: 2016.
    • (2016) The Netherlands
    • Smits, L.1    Derikx, L.2    Drenth, J.3    de Jong, D.4    van Esch, A.5    Hoentjen, F.6
  • 49
    • 85012255168 scopus 로고    scopus 로고
    • Clinical outcomes following a switch from Remicade® to the biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study
    • PID: 27095751
    • Smits LJT, Derikx LAAP, de Jong DJ, Boshuizen RS, van Esch AAJ, Drenth JPH, et al. Clinical outcomes following a switch from Remicade® to the biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study. J Crohns Colitis. 2016;10:1287–93.
    • (2016) J Crohns Colitis , vol.10 , pp. 1287-1293
    • Smits, L.J.T.1    Derikx, L.A.A.P.2    de Jong, D.J.3    Boshuizen, R.S.4    van Esch, A.A.J.5    Drenth, J.P.H.6
  • 50
    • 85021234656 scopus 로고    scopus 로고
    • Safety and efficacy of infliximab biosimilar (Remsima©) in Crohn’s disease patients in clinical practice: results after 6 months of treatment. 11th Congress of the European Crohn’s and Colitis Organisation; Amsterdam
    • Guerra Veloz MF, Argüelles Arias F, Perea Amarillo R, Castro Laria L, Maldonado Pérez MB, Benítez Roldán A, et al. Safety and efficacy of infliximab biosimilar (Remsima©) in Crohn’s disease patients in clinical practice: results after 6 months of treatment. 11th Congress of the European Crohn’s and Colitis Organisation; Amsterdam, The Netherlands: 2016a.
    • (2016) The Netherlands
    • Guerra Veloz, M.F.1    Argüelles Arias, F.2    Perea Amarillo, R.3    Castro Laria, L.4    Maldonado Pérez, M.B.5    Benítez Roldán, A.6
  • 51
    • 85021202424 scopus 로고    scopus 로고
    • Switching of patients with inflammatory bowel disease from original infliximab (Remicade®) to biosimilar infliximab (Remsima™) is effective and safe. 11th Congress of the European Crohn’s and Colitis Organisation; Amsterdam
    • Kolar M, Duricová D, Brotlik M, Hruba V, Machkova N, Mitrova K, et al. Switching of patients with inflammatory bowel disease from original infliximab (Remicade®) to biosimilar infliximab (Remsima™) is effective and safe. 11th Congress of the European Crohn’s and Colitis Organisation; Amsterdam, The Netherlands: 2016.
    • (2016) The Netherlands
    • Kolar, M.1    Duricová, D.2    Brotlik, M.3    Hruba, V.4    Machkova, N.5    Mitrova, K.6
  • 52
    • 85021206753 scopus 로고    scopus 로고
    • Switching of patients with inflammatory bowel disease from original infliximab (Remicade®) to biosimilar infliximab (Remsima™) is effective and safe—one-year follow-up. United European Gastroenterology Week; Vienna
    • Kolar M, Duricová D, Bortlik M, Hruba V, Machkova N, Mitrova K, et al. Switching of patients with inflammatory bowel disease from original infliximab (Remicade®) to biosimilar infliximab (Remsima™) is effective and safe—one-year follow-up. United European Gastroenterology Week; Vienna, Austria; United European Gastroenterol J: 2016.
    • (2016) Austria; United European Gastroenterol J
    • Kolar, M.1    Duricová, D.2    Bortlik, M.3    Hruba, V.4    Machkova, N.5    Mitrova, K.6
  • 53
    • 85021234656 scopus 로고    scopus 로고
    • Safety and efficacy of infliximab biosimilar (Remsima©) in ulcerative colitis disease patients in clinical practice: results after 6-months treatment. 11th Congress of the European Crohn’s and Colitis Organisation; Amsterdam
    • Guerra Veloz MF, Argüelles Arias F, Perea Amarillo R, Castro Laria L, Maldonado Pérez MB, Benítez Roldán A, et al. Safety and efficacy of infliximab biosimilar (Remsima©) in ulcerative colitis disease patients in clinical practice: results after 6-months treatment. 11th Congress of the European Crohn’s and Colitis Organisation; Amsterdam, The Netherlands: 2016b.
    • (2016) The Netherlands
    • Guerra Veloz, M.F.1    Argüelles Arias, F.2    Perea Amarillo, R.3    Castro Laria, L.4    Maldonado Pérez, M.B.5    Benítez Roldán, A.6
  • 55
    • 84997758657 scopus 로고    scopus 로고
    • Preliminary assessment of efficacy and safety of switching between originator and biosimilar infliximab in paediatric Crohn disease patients. 46th Annual Digestive Disease Week; Washington DC
    • Kierkus J. Preliminary assessment of efficacy and safety of switching between originator and biosimilar infliximab in paediatric Crohn disease patients. 46th Annual Digestive Disease Week; Washington DC, USA; Gastroenterology: 2015. doi:10.1016/S0016-5085(15)32670-6.
    • (2015) USA; Gastroenterology
    • Kierkus, J.1
  • 58
    • 85021234169 scopus 로고    scopus 로고
    • Biosimilar infliximab CT-P13 treatment in patients with inflammatory bowel diseases: a 1-year, single-centre retrospective study. 11th Congress of the European Crohn’s and Colitis Organisation; Amsterdam
    • Hlavaty T, Krajcovicova A, Sturdik I, Letkovsky J, Koller T, Toth J, et al. Biosimilar infliximab CT-P13 treatment in patients with inflammatory bowel diseases: a 1-year, single-centre retrospective study. 11th Congress of the European Crohn’s and Colitis Organisation; Amsterdam, The Netherlands: 2016.
    • (2016) The Netherlands
    • Hlavaty, T.1    Krajcovicova, A.2    Sturdik, I.3    Letkovsky, J.4    Koller, T.5    Toth, J.6
  • 60
    • 84934294253 scopus 로고    scopus 로고
    • Clinical experience of the use of CT-P13, a biosimilar to infliximab in patients with inflammatory bowel disease: a case series
    • COI: 1:CAS:528:DC%2BC2cXhvVamsr3J, PID: 25326115
    • Kang YS, Moon HH, Lee SE, Lim YJ, Kang HW. Clinical experience of the use of CT-P13, a biosimilar to infliximab in patients with inflammatory bowel disease: a case series. Dig Dis Sci. 2015;60:951–6. doi:10.1007/s10620-014-3392-z.
    • (2015) Dig Dis Sci , vol.60 , pp. 951-956
    • Kang, Y.S.1    Moon, H.H.2    Lee, S.E.3    Lim, Y.J.4    Kang, H.W.5
  • 61
    • 85021242056 scopus 로고    scopus 로고
    • What future for biosimilars in inflammatory bowel diseases?
    • National Congress; Palermo, Italy
    • Armuzzi A. What future for biosimilars in inflammatory bowel diseases? The Italian Group for the study of Inflammatory Bowel Disease VII National Congress; Palermo, Italy: 2015.
    • (2015) The Italian Group for the study of Inflammatory Bowel Disease , vol.7
    • Armuzzi, A.1
  • 62
    • 85021231286 scopus 로고    scopus 로고
    • Prospective observational study on inflammatory bowel disease patients treated with infliximab biosimilars: preliminary results of the PROSIT-BIO cohort of the IG-IBD. 11th Congress of the European Crohn’s and Colitis Organisation; Amsterdam
    • Fiorino G, Manetti N, Variola A, Bossa F, Rizzuto G, Guidi L, et al. Prospective observational study on inflammatory bowel disease patients treated with infliximab biosimilars: preliminary results of the PROSIT-BIO cohort of the IG-IBD. 11th Congress of the European Crohn’s and Colitis Organisation; Amsterdam, The Netherlands: 2016. doi:10.1097/MIB.0000000000000995.
    • (2016) The Netherlands
    • Fiorino, G.1    Manetti, N.2    Variola, A.3    Bossa, F.4    Rizzuto, G.5    Guidi, L.6
  • 63
    • 84942325078 scopus 로고    scopus 로고
    • Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea
    • Park SH, Kim YH, Lee JH, Kwon HJ, Lee SH, Park DI, et al. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. Exp Rev Gastroenterol Hepatol. 2015;9(Suppl 1):35–44.
    • (2015) Exp Rev Gastroenterol Hepatol , vol.9 , pp. 35-44
    • Park, S.H.1    Kim, Y.H.2    Lee, J.H.3    Kwon, H.J.4    Lee, S.H.5    Park, D.I.6
  • 64
    • 84995578185 scopus 로고    scopus 로고
    • The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis
    • COI: 1:CAS:528:DC%2BC28Xht1ygsr7O, PID: 27473452
    • Dapavo PMD, Vujic IMD, Fierro MTMD, Quaglino PMD, Sanlorenzo MMD. The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75:736–9. doi:10.1016/j.jaad.2016.04.068.
    • (2016) J Am Acad Dermatol , vol.75 , pp. 736-739
    • Dapavo, P.M.D.1    Vujic, I.M.D.2    Fierro, M.T.M.D.3    Quaglino, P.M.D.4    Sanlorenzo, M.M.D.5
  • 65
    • 85011398033 scopus 로고    scopus 로고
    • Biosimilar infliximab (CT-P13) is not inferior to originator Infliximab: results from the 52-week randomized NOR-SWITCH trial. United European Gastroenterology Week; Vienna, Austria
    • The NOR-SWITCH study is the largest clinical trial of switching from infliximab to CT-P13 and includes patients from multiple indications. This study provides important efficacy, safety and immunogenicity data on switching
    • • Jørgensen K, Olsen I, Goll G, Lorentzen M, Bolstad N, Haavardsholm E, et al. Biosimilar infliximab (CT-P13) is not inferior to originator Infliximab: results from the 52-week randomized NOR-SWITCH trial. United European Gastroenterology Week; Vienna, Austria; United European Gastroenterol J: 2016. The NOR-SWITCH study is the largest clinical trial of switching from infliximab to CT-P13 and includes patients from multiple indications. This study provides important efficacy, safety and immunogenicity data on switching.
    • (2016) United European Gastroenterol J
    • Jørgensen, K.1    Olsen, I.2    Goll, G.3    Lorentzen, M.4    Bolstad, N.5    Haavardsholm, E.6
  • 66
    • 85021195033 scopus 로고    scopus 로고
    • Biosimilar infliximab (CT-P13) is not inferior to originator infliximab: results from a 52-week randomized switch trial in Norway
    • Washington DC, USA; Arthritis Rheumatol: 2016. The NOR-SWITCH study is the largest clinical trial of switching from infliximab to CT-P13 and includes patients from multiple indications. This study provides important efficacy, safety and immunogenicity data on switching
    • • Goll GL, Olsen IC, Jorgensen KK, Lorentzen M, Bolstad N, Haavardsholm EA, et al. Biosimilar infliximab (CT-P13) is not inferior to originator infliximab: results from a 52-week randomized switch trial in Norway. American College of Rheumatology 2016; Washington DC, USA; Arthritis Rheumatol: 2016. The NOR-SWITCH study is the largest clinical trial of switching from infliximab to CT-P13 and includes patients from multiple indications. This study provides important efficacy, safety and immunogenicity data on switching.
    • (2016) American College of Rheumatology
    • Goll, G.L.1    Olsen, I.C.2    Jorgensen, K.K.3    Lorentzen, M.4    Bolstad, N.5    Haavardsholm, E.A.6
  • 67
    • 84946601256 scopus 로고    scopus 로고
    • Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseases: response to: Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data
    • Expert Opin Biol Ther. 2016;16:1311-2
    • Gentileschi S, Barreca C, Bellisai F, Biasi G, Brizi MG, De Stefano R, et al. Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseases: response to: Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15:1677–83. Expert Opin Biol Ther. 2016;16:1311-2
    • (2015) Expert Opin Biol Ther , vol.15 , pp. 1677-1683
    • Gentileschi, S.1    Barreca, C.2    Bellisai, F.3    Biasi, G.4    Brizi, M.G.5    De Stefano, R.6
  • 72
    • 85021242075 scopus 로고    scopus 로고
    • An open-label, multicentre, phase IV study to investigate the infliximab serum concentration of Remsima™ (infliximab biosimilar) after switching from Remicade (infliximab) in subjects with Crohn’s Disease (CD)
    • Accessed 22 Mar
    • EU Clinical Trials Register. An open-label, multicentre, phase IV study to investigate the infliximab serum concentration of Remsima™ (infliximab biosimilar) after switching from Remicade (infliximab) in subjects with Crohn’s Disease (CD), Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA) in stable remission. http://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004904-31/NL. Accessed 22 Mar 2016.
    • (2016) Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA) in stable remission
  • 73
    • 85017017931 scopus 로고    scopus 로고
    • Comparable safety and immunogenicity and sustained efficacy after transition to SB2 (an infliximab biosimilar) vs ongoing infliximab reference product in patients with rheumatoid arthritis: results of phase III transition study
    • London, UK; Ann Rheum Dis: 2016. doi:. Only published study to date of switching from infliximab to SB2. This study provides important efficacy, safety and immunogenicity data on switching
    • • Smolen J, Choe JY, Prodanovic N, Niebrzdowski J, Staykov I, Dokoupilova E, et al. Comparable safety and immunogenicity and sustained efficacy after transition to SB2 (an infliximab biosimilar) vs ongoing infliximab reference product in patients with rheumatoid arthritis: results of phase III transition study. European League Against Rheumatism 2016; London, UK; Ann Rheum Dis: 2016. doi:10.1136/annrheumdis-2016-eular.3122. Only published study to date of switching from infliximab to SB2. This study provides important efficacy, safety and immunogenicity data on switching.
    • (2016) European League Against Rheumatism
    • Smolen, J.1    Choe, J.Y.2    Prodanovic, N.3    Niebrzdowski, J.4    Staykov, I.5    Dokoupilova, E.6
  • 74
    • 85021212361 scopus 로고    scopus 로고
    • Comparable safety and immunogenicity and sustained efficacy after transition to SB2 (an infliximab biosimilar) vs ongoing reference infliximab (Remicade®) in patients with rheumatoid arthritis: results of phase III transition study
    • Washington DC, USA: 2016. Only published study to date of switching from infliximab to SB2. This study provides important efficacy, safety and immunogenicity data on switching
    • • Smolen JS, Choe JY, Prodanovic N, Niebrzydowski J, Staykov I, Dokoupilova E, et al. Comparable safety and immunogenicity and sustained efficacy after transition to SB2 (an infliximab biosimilar) vs ongoing reference infliximab (Remicade®) in patients with rheumatoid arthritis: results of phase III transition study. American College of Rheumatology 2016; Washington DC, USA: 2016. Only published study to date of switching from infliximab to SB2. This study provides important efficacy, safety and immunogenicity data on switching.
    • (2016) American College of Rheumatology
    • Smolen, J.S.1    Choe, J.Y.2    Prodanovic, N.3    Niebrzydowski, J.4    Staykov, I.5    Dokoupilova, E.6
  • 75
    • 85021191319 scopus 로고    scopus 로고
    • Infliximab biosimilar in the treatment of inflammatory bowel disease: a Japanese single-cohort observational study. 11th Congress of the European Crohn’s and Colitis Organisation; Amsterdam
    • Hamanaka S, Nakagawa T, Koseki H, Sakurai T, Taida T, Okimoto K, et al. Infliximab biosimilar in the treatment of inflammatory bowel disease: a Japanese single-cohort observational study. 11th Congress of the European Crohn’s and Colitis Organisation; Amsterdam, The Netherlands: 2016.
    • (2016) The Netherlands
    • Hamanaka, S.1    Nakagawa, T.2    Koseki, H.3    Sakurai, T.4    Taida, T.5    Okimoto, K.6
  • 76
    • 85021232454 scopus 로고    scopus 로고
    • Efficacy and safety of switching between originator and biosimilar infliximab in patients with inflammatory bowel disease in practical clinic: results to 6 months. 11th Congress of the European Crohn’s and Colitis Organisation; Amsterdam
    • Díaz Hernández L, Rodríguez González GE, Vela González M, Tardillo Marín CA, Rodríguez Díaz CY, Arranz Hernández L et al. Efficacy and safety of switching between originator and biosimilar infliximab in patients with inflammatory bowel disease in practical clinic: results to 6 months. 11th Congress of the European Crohn’s and Colitis Organisation; Amsterdam, The Netherlands: 2016. doi:10.1093/ecco-jcc/jjw019.568.
    • (2016) The Netherlands
    • Díaz Hernández, L.1    Rodríguez González, G.E.2    Vela González, M.3    Tardillo Marín, C.A.4    Rodríguez Díaz, C.Y.5    Arranz Hernández, L.6
  • 78
    • 85021210331 scopus 로고    scopus 로고
    • Longterm safety and efficacy of SB4 (etanercept biosimilar) in patients with rheumatoid arthritis: comparison between continuing SB4 and switching from etanercept reference product to SB4
    • London, UK; Ann Rheum Dis: 2016. Only published study to date of switching from etanercept to SB4 in patients with RA. This study provides important efficacy, safety and immunogenicity data on switching
    • • Emery P, Vencovský J, Sylwestrzak A, Leszczynski P, Porawska W, Stasiuk B, et al. Longterm safety and efficacy of SB4 (etanercept biosimilar) in patients with rheumatoid arthritis: comparison between continuing SB4 and switching from etanercept reference product to SB4. European League Against Rheumatism 2016; London, UK; Ann Rheum Dis: 2016. Only published study to date of switching from etanercept to SB4 in patients with RA. This study provides important efficacy, safety and immunogenicity data on switching.
    • (2016) European League Against Rheumatism
    • Emery, P.1    Vencovský, J.2    Sylwestrzak, A.3    Leszczynski, P.4    Porawska, W.5    Stasiuk, B.6
  • 79
    • 85021191189 scopus 로고    scopus 로고
    • Additional efficacy results of SB4 (etanercept biosimilar) up to week 100: comparison between continuing SB4 and switching from reference etanercept (Enbrel®) to SB4
    • Washington DC, USA: 2016. Ann Rheum Dis: 2016;75(Suppl2):236. Only published study to date of switching from etanercept to SB4 in patients with RA. This study provides important efficacy, safety and immunogenicity data on switching
    • • Emery P, Vencovský J, Sylwestrzak A, Leszczynski P, Porawska W, Stasiuk B, et al. Additional efficacy results of SB4 (etanercept biosimilar) up to week 100: comparison between continuing SB4 and switching from reference etanercept (Enbrel®) to SB4. American College of Rheumatology 2016; Washington DC, USA: 2016. Ann Rheum Dis: 2016;75(Suppl2):236. Only published study to date of switching from etanercept to SB4 in patients with RA. This study provides important efficacy, safety and immunogenicity data on switching.
    • (2016) American College of Rheumatology
    • Emery, P.1    Vencovský, J.2    Sylwestrzak, A.3    Leszczynski, P.4    Porawska, W.5    Stasiuk, B.6
  • 80
    • 84976601138 scopus 로고    scopus 로고
    • A randomised Phase l pharmacokinetic study comparing SB4 and etanercept reference product (Enbrel(R)) in healthy subjects
    • Lee Y, Shin D, Kim Y, Kang J, Gauliard A, Fuhr R. A randomised Phase l pharmacokinetic study comparing SB4 and etanercept reference product (Enbrel(R)) in healthy subjects. Br J Clin Pharmacol. 2016;82:64–73. doi:10.1111/bcp.12929.
    • (2016) Br J Clin Pharmacol , vol.82 , pp. 64-73
    • Lee, Y.1    Shin, D.2    Kim, Y.3    Kang, J.4    Gauliard, A.5    Fuhr, R.6
  • 81
    • 85021242448 scopus 로고    scopus 로고
    • A phase I pharmacokinetic study comparing SB4, an etanercept biosimilar, and etanercept reference product (Enbrel®) in healthy male subjects
    • Rome, Italy; Ann Rheum Dis
    • Lee YJ, Shin D, Kim Y, Kang JW, Fuhr R, Gauliard A. A phase I pharmacokinetic study comparing SB4, an etanercept biosimilar, and etanercept reference product (Enbrel®) in healthy male subjects. European League Against Rheumatism 2015; Rome, Italy; Ann Rheum Dis: 2015.
    • (2015) European League Against Rheumatism , vol.2015
    • Lee, Y.J.1    Shin, D.2    Kim, Y.3    Kang, J.W.4    Fuhr, R.5    Gauliard, A.6
  • 83
    • 85014009195 scopus 로고    scopus 로고
    • The EGALITY study: a confirmatory, randomised, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, versus the originator product in patients with moderate to severe chronic plaque-type psoriasis
    • Only published study to date of switching from etanercept to GP2015 in patients. Interchangeability design with 2 control treatment arms allows effect of multiple switching to be assessed. This study also provides important efficacy, safety and immunogenicity data on switching
    • • Griffiths CE, Thaci D, Gerdes S, Arenberger P, Pulka G, Kingo K, et al. The EGALITY study: a confirmatory, randomised, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, versus the originator product in patients with moderate to severe chronic plaque-type psoriasis. Br J Dermatol. 2017;176:928–38. Only published study to date of switching from etanercept to GP2015 in patients. Interchangeability design with 2 control treatment arms allows effect of multiple switching to be assessed. This study also provides important efficacy, safety and immunogenicity data on switching.
    • (2017) Br J Dermatol , vol.176 , pp. 928-938
    • Griffiths, C.E.1    Thaci, D.2    Gerdes, S.3    Arenberger, P.4    Pulka, G.5    Kingo, K.6
  • 84
    • 85021220815 scopus 로고    scopus 로고
    • Pharmacokinetics and safety of GP2015, a proposed etanercept biosimilar, and etanercept originator product in healthy male subjects: a randomised twoway crossover study
    • London: UK; Ann Rheum Dis
    • Afonso M, Sanguino Heinrich S, Poetzl J, Woehling H. Pharmacokinetics and safety of GP2015, a proposed etanercept biosimilar, and etanercept originator product in healthy male subjects: a randomised twoway crossover study. European League Against Rheumatism 2016; London, UK; Ann Rheum Dis: 2016. doi:10.1136/annrheumdis-2016-eular.1422.
    • (2016) European League Against Rheumatism , vol.2016
    • Afonso, M.1    Sanguino Heinrich, S.2    Poetzl, J.3    Woehling, H.4
  • 86
    • 84860619510 scopus 로고    scopus 로고
    • Comparative pharmacokinetics of HD203, a biosimilar of etanercept, with marketed etanercept (Enbrel(R)): a double-blind, single-dose, crossover study in healthy volunteers
    • COI: 1:CAS:528:DC%2BC38XhtVSqtLzN, PID: 22515513
    • Yi S, Kim SE, Park MK, Yoon SH, Cho JY, Lim KS, et al. Comparative pharmacokinetics of HD203, a biosimilar of etanercept, with marketed etanercept (Enbrel(R)): a double-blind, single-dose, crossover study in healthy volunteers. BioDrugs. 2012;26:177–84. doi:10.2165/11631860-000000000-00000.
    • (2012) BioDrugs , vol.26 , pp. 177-184
    • Yi, S.1    Kim, S.E.2    Park, M.K.3    Yoon, S.H.4    Cho, J.Y.5    Lim, K.S.6
  • 88
    • 85021233226 scopus 로고    scopus 로고
    • LBEC0101, an etanercept biosimilar, showed comparable tolerability and pharmacokinetic profiles to those of etanercept in healthy male volunteers. 115th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; Atlanta, Georgia
    • Chung H, Ahn L, Choi Y, Shin S, Jang I, Yu K, et al. LBEC0101, an etanercept biosimilar, showed comparable tolerability and pharmacokinetic profiles to those of etanercept in healthy male volunteers. 115th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; Atlanta, Georgia, USA; Clin Pharmacol Ther. 95:S5–S6.
    • USA; Clin Pharmacol Ther , vol.95 , pp. S5-S6
    • Chung, H.1    Ahn, L.2    Choi, Y.3    Shin, S.4    Jang, I.5    Yu, K.6
  • 91
    • 85021211627 scopus 로고    scopus 로고
    • Comparative pharmacokinetics/tolerability of TuNEX and Enbrel® in healthy Korean volunteers. 111th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; Atlanta, Georgia
    • Gu N, Kim BR, Kim BH, Kim JW, Song DH, Shin SG, et al. Comparative pharmacokinetics/tolerability of TuNEX and Enbrel® in healthy Korean volunteers. 111th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; Atlanta, Georgia, USA; Clin Pharmacol Ther: 2010.
    • (2010) USA; Clin Pharmacol Ther
    • Gu, N.1    Kim, B.R.2    Kim, B.H.3    Kim, J.W.4    Song, D.H.5    Shin, S.G.6
  • 92
    • 83455201580 scopus 로고    scopus 로고
    • Comparative pharmacokinetics and tolerability of branded etanercept (25 mg) and its biosimilar (25 mg): a randomized, open-label, single-dose, two-sequence, crossover study in healthy Korean male volunteers
    • COI: 1:CAS:528:DC%2BC3MXhs1CjtLvF, PID: 22088414
    • Gu N, Yi S, Kim TE, Kim J, Shin SG, Jang IJ, et al. Comparative pharmacokinetics and tolerability of branded etanercept (25 mg) and its biosimilar (25 mg): a randomized, open-label, single-dose, two-sequence, crossover study in healthy Korean male volunteers. Clin Ther. 2011;33:2029–37. doi:10.1016/j.clinthera.2011.10.022.
    • (2011) Clin Ther , vol.33 , pp. 2029-2037
    • Gu, N.1    Yi, S.2    Kim, T.E.3    Kim, J.4    Shin, S.G.5    Jang, I.J.6
  • 93
    • 85021212378 scopus 로고    scopus 로고
    • ABP 501 long-term safety/efficacy: interim results from an open-label extension study
    • Washington DC, USA; 2016;68(suppl 10). Accessed 17 May 2017. Only published study to date of switching from adalimumab to ABP 501 in patients with RA. This study provides important efficacy, safety and immunogenicity data on switching
    • • Cohen S, Pablos JL, Zhang N, Rizzo W, Muller G, Padmanaban D, et al. ABP 501 long-term safety/efficacy: interim results from an open-label extension study. American College of Rheumatology 2016; Washington DC, USA; 2016;68(suppl 10). http://acrabstracts.org/abstract/abp-501-long-term-safetyefficacy-interim-results-from-an-open-label-extension-study/. Accessed 17 May 2017. Only published study to date of switching from adalimumab to ABP 501 in patients with RA. This study provides important efficacy, safety and immunogenicity data on switching.
    • (2016) American College of Rheumatology
    • Cohen, S.1    Pablos, J.L.2    Zhang, N.3    Rizzo, W.4    Muller, G.5    Padmanaban, D.6
  • 94
    • 85021186601 scopus 로고    scopus 로고
    • Evaluation of efficacy and safety of ABP 501 in a phase 3 study in subjects with moderate to severe plaque psoriasis: 52-week results. American Academy of Dermatology 74th Annual Meeting; Washington DC
    • Strober B, Foley P, Kaur P, Philipp S, Zhang N. Evaluation of efficacy and safety of ABP 501 in a phase 3 study in subjects with moderate to severe plaque psoriasis: 52-week results. American Academy of Dermatology 74th Annual Meeting; Washington DC, USA; J Am Acad Dermatol: 2016.
    • (2016) USA; J Am Acad Dermatol
    • Strober, B.1    Foley, P.2    Kaur, P.3    Philipp, S.4    Zhang, N.5
  • 95
    • 85021211835 scopus 로고    scopus 로고
    • Single transition from adalimumab to ABP 501: evaluation of immunogenicity in a phase 3 study in subjects with moderate to severe plaque psoriasis. American Academy of Dermatology 74th Annual Meeting; Washington DC
    • Gooderham M, Constanzo A, Kaliaperumal A, Kaur P, Narbutt J, Spelman L, et al. Single transition from adalimumab to ABP 501: evaluation of immunogenicity in a phase 3 study in subjects with moderate to severe plaque psoriasis. American Academy of Dermatology 74th Annual Meeting; Washington DC, USA; J Am Acad Dermatol: 2016.
    • (2016) USA; J Am Acad Dermatol
    • Gooderham, M.1    Constanzo, A.2    Kaliaperumal, A.3    Kaur, P.4    Narbutt, J.5    Spelman, L.6
  • 96
    • 85021240490 scopus 로고    scopus 로고
    • Sustained efficacy and comparable safety and immunogenicity after transition to SB5 (an adalimumab biosimilar) vs continuation of the adalimumab reference product in patients with rheumatoid arthritis: result of phase III study
    • London, UK; Ann Rheum Dis: 2016. Only published study to date of switching from adalimumab to SB5 in patients with RA. This study provides important immunogenicity data on switching, although efficacy and safety data are lacking
    • • Weinblatt M, Baranauskaite A, Niebrzydowski J, Dokoupilova E, Zielinska A, Sitek-Ziolkowska K, et al. Sustained efficacy and comparable safety and immunogenicity after transition to SB5 (an adalimumab biosimilar) vs continuation of the adalimumab reference product in patients with rheumatoid arthritis: result of phase III study. European League Against Rheumatism 2016; London, UK; Ann Rheum Dis: 2016. Only published study to date of switching from adalimumab to SB5 in patients with RA. This study provides important immunogenicity data on switching, although efficacy and safety data are lacking.
    • (2016) European League Against Rheumatism
    • Weinblatt, M.1    Baranauskaite, A.2    Niebrzydowski, J.3    Dokoupilova, E.4    Zielinska, A.5    Sitek-Ziolkowska, K.6
  • 97
    • 85021238538 scopus 로고    scopus 로고
    • Efficacy after transition to SB5 from reference adalimumab (Humira®) vs. continuation of SB5 or reference adalimumab by antibodies developed after transition from a SB5 phase III study
    • Washington DC, USA: 2016. Only published study to date of switching from adalimumab to SB5 in patients with RA. This study provides important immunogenicity data on switching, although efficacy and safety data are lacking
    • • Genovese MC, Weinblatt M, Keystone EC, Baranauskaite A, Cheong SY, Ghil J. Efficacy after transition to SB5 from reference adalimumab (Humira®) vs. continuation of SB5 or reference adalimumab by antibodies developed after transition from a SB5 phase III study. American College of Rheumatology 2016; Washington DC, USA: 2016. Only published study to date of switching from adalimumab to SB5 in patients with RA. This study provides important immunogenicity data on switching, although efficacy and safety data are lacking.
    • (2016) although efficacy and safety data are lackingAmerican College of Rheumatology
    • Genovese, M.C.1    Weinblatt, M.2    Keystone, E.C.3    Baranauskaite, A.4    Cheong, S.Y.5    Ghil, J.6
  • 99
    • 85013244232 scopus 로고    scopus 로고
    • Efficacy and safety of switched CT-P10 from innovator rituximab compared to those of maintained CT-P10 in patients with rheumatoid arthritis up to 56 weeks
    • Only published study to date of switching from rituximab to CT-P10 in patients with RA. This study provides important efficacy and safety data on switching, although immunogenicity data are lacking
    • • Yoo DH, Park W, Suh CH, Shim SC, Cons Molina F, Jeka S, et al. Efficacy and safety of switched CT-P10 from innovator rituximab compared to those of maintained CT-P10 in patients with rheumatoid arthritis up to 56 weeks. American College of Rheumatology 2015; San Francisco, California, USA; Arthritis Rheumatol: 2015. Only published study to date of switching from rituximab to CT-P10 in patients with RA. This study provides important efficacy and safety data on switching, although immunogenicity data are lacking.
    • (2015) American College of Rheumatology 2015; San Francisco, California, USA; Arthritis Rheumatol
    • Yoo, D.H.1    Park, W.2    Suh, C.H.3    Shim, S.C.4    Cons Molina, F.5    Jeka, S.6
  • 101
    • 84962037330 scopus 로고    scopus 로고
    • A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study
    • Yoo DH, Racewicz A, Brzezicki J, Yatsyshyn R, Arteaga ET, Baranauskaite A, et al. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Res Ther. 2016;18:1–12.
    • (2016) Arthritis Res Ther , vol.18 , pp. 1-12
    • Yoo, D.H.1    Racewicz, A.2    Brzezicki, J.3    Yatsyshyn, R.4    Arteaga, E.T.5    Baranauskaite, A.6
  • 102
    • 84954568420 scopus 로고    scopus 로고
    • Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study
    • PID: 26795209
    • Park W, Yoo DH, Jaworski J, Brzezicki J, Gnylorybov A, Kadinov V, et al. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. Arthritis Res Ther. 2016;18:25.
    • (2016) Arthritis Res Ther , vol.18 , pp. 25
    • Park, W.1    Yoo, D.H.2    Jaworski, J.3    Brzezicki, J.4    Gnylorybov, A.5    Kadinov, V.6
  • 103
    • 84947032856 scopus 로고    scopus 로고
    • Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis
    • COI: 1:CAS:528:DC%2BC2MXhvV2ktLvK, PID: 25736355
    • Takeuchi T, Yamanaka H, Tanaka Y, Sakurai T, Saito K, Ohtsubo H, et al. Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2015;25:817–24. doi:10.3109/14397595.2015.1022297.
    • (2015) Mod Rheumatol , vol.25 , pp. 817-824
    • Takeuchi, T.1    Yamanaka, H.2    Tanaka, Y.3    Sakurai, T.4    Saito, K.5    Ohtsubo, H.6
  • 104
    • 84883746909 scopus 로고    scopus 로고
    • A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study
    • COI: 1:CAS:528:DC%2BC3sXhs1eis7nM, PID: 23687259
    • Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72:1605–12. doi:10.1136/annrheumdis-2012-203091.
    • (2013) Ann Rheum Dis , vol.72 , pp. 1605-1612
    • Park, W.1    Hrycaj, P.2    Jeka, S.3    Kovalenko, V.4    Lysenko, G.5    Miranda, P.6
  • 105
    • 77953177072 scopus 로고    scopus 로고
    • A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis
    • PID: 20231198
    • Inman RD, Maksymowych WP. A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis. J Rheumatol. 2010;37:1203–10. doi:10.3899/jrheum.091042.
    • (2010) J Rheumatol , vol.37 , pp. 1203-1210
    • Inman, R.D.1    Maksymowych, W.P.2
  • 106
    • 54949091496 scopus 로고    scopus 로고
    • Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period
    • COI: 1:CAS:528:DC%2BD1cXhtlKqsbzO, PID: 18759257
    • Braun J, Deodhar A, Dijkmans B, Geusens P, Sieper J, Williamson P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis Rheum. 2008;59:1270–8. doi:10.1002/art.24001.
    • (2008) Arthritis Rheum , vol.59 , pp. 1270-1278
    • Braun, J.1    Deodhar, A.2    Dijkmans, B.3    Geusens, P.4    Sieper, J.5    Williamson, P.6
  • 107
    • 38149024172 scopus 로고    scopus 로고
    • Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment
    • COI: 1:CAS:528:DC%2BD1cXhslOjtr4%3D, PID: 18163509
    • Breban M, Ravaud P, Claudepierre P, Baron G, Henry YD, Hudry C, et al. Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum. 2008;58:88–97. doi:10.1002/art.23167.
    • (2008) Arthritis Rheum , vol.58 , pp. 88-97
    • Breban, M.1    Ravaud, P.2    Claudepierre, P.3    Baron, G.4    Henry, Y.D.5    Hudry, C.6
  • 108
    • 33745600393 scopus 로고    scopus 로고
    • Continuation of treatment with infliximab in ankylosing spondylitis: 2-yr open follow-up
    • COI: 1:CAS:528:DC%2BD28Xmt1Wrsrc%3D
    • Gossec L, Le Henanff A, Breban M, Vignon E, Claudepierre P, Devauchelle V, et al. Continuation of treatment with infliximab in ankylosing spondylitis: 2-yr open follow-up. Rheumatology (Oxford). 2006;45:859–62. doi:10.1093/rheumatology/kel015.
    • (2006) Rheumatology (Oxford) , vol.45 , pp. 859-862
    • Gossec, L.1    Le Henanff, A.2    Breban, M.3    Vignon, E.4    Claudepierre, P.5    Devauchelle, V.6
  • 109
    • 19944432148 scopus 로고    scopus 로고
    • Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis
    • COI: 1:CAS:528:DC%2BD2MXhvFyrtbk%3D, PID: 15388511
    • Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, et al. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis. 2005;64:229–34.
    • (2005) Ann Rheum Dis , vol.64 , pp. 229-234
    • Braun, J.1    Brandt, J.2    Listing, J.3    Zink, A.4    Alten, R.5    Burmester, G.6
  • 110
    • 0345490895 scopus 로고    scopus 로고
    • Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study
    • COI: 1:STN:280:DC%2BD3srmsVKgsw%3D%3D, PID: 14644863
    • Temekonidis TI, Alamanos Y, Nikas SN, Bougias DV, Georgiadis AN, Voulgari PV, et al. Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study. Ann Rheum Dis. 2003;62:1218–20.
    • (2003) Ann Rheum Dis , vol.62 , pp. 1218-1220
    • Temekonidis, T.I.1    Alamanos, Y.2    Nikas, S.N.3    Bougias, D.V.4    Georgiadis, A.N.5    Voulgari, P.V.6
  • 111
    • 85021206793 scopus 로고    scopus 로고
    • A phase III, randomized, double-blind clinical study comparing SB4, an etanercept biosimilar, with etanercept reference product (Enbrel®) in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy (52-week results)
    • San Francisco, California, USA; Arthritis Rheum
    • Vencovský J, Sylwestrzak A, Leszczyński P, Porawska W, Baranauskaite A, Tseluyko V, et al. A phase III, randomized, double-blind clinical study comparing SB4, an etanercept biosimilar, with etanercept reference product (Enbrel®) in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy (52-week results). American College of Rheumatology 2015; San Francisco, California, USA; Arthritis Rheum: 2015. doi:10.1136/annrheumdis-2015-eular.1220.
    • (2015) American College of Rheumatology , vol.2015
    • Vencovský, J.1    Sylwestrzak, A.2    Leszczyński, P.3    Porawska, W.4    Baranauskaite, A.5    Tseluyko, V.6
  • 112
    • 84978765827 scopus 로고    scopus 로고
    • Difference between enbrel and benepali treatment groups in ‘hepatobiliary disorders’
    • PID: 27432354
    • Scheinberg M, Azevedo V. Difference between enbrel and benepali treatment groups in ‘hepatobiliary disorders’. Ann Rheum Dis. 2016;75:e64. doi:10.1136/annrheumdis-2016-210101.
    • (2016) Ann Rheum Dis , vol.75
    • Scheinberg, M.1    Azevedo, V.2
  • 113
    • 84990246948 scopus 로고    scopus 로고
    • Difference between SB4 and reference etanercept in the hepatobiliary disorders not considered to be caused by SB4: response to letter by Scheinberg and Azevedo
    • Emery P, Vencovský J, Ghil J, Cheong SY, Rho YH. Difference between SB4 and reference etanercept in the hepatobiliary disorders not considered to be caused by SB4: response to letter by Scheinberg and Azevedo. Ann Rheum Dis. 2016;75:e65. doi:10.1136/annrheumdis-2016-210127.
    • (2016) Ann Rheum Dis , vol.e65 , pp. 75
    • Emery, P.1    Vencovský, J.2    Ghil, J.3    Cheong, S.Y.4    Rho, Y.H.5
  • 114
    • 85021200743 scopus 로고    scopus 로고
    • A randomized, controlled, multicenter, 2-arm, parallel-group, double-blind study to demonstrate the equivalence of CT-P10 to innovator rituximab with respect to pharmacokinetic profile in patients with rheumatoid arthritis
    • San Diego, California, USA
    • Yoo DH, Park W, Jeka S, Cons Molina F, Hrycaj P, Wiland P, et al. A randomized, controlled, multicenter, 2-arm, parallel-group, double-blind study to demonstrate the equivalence of CT-P10 to innovator rituximab with respect to pharmacokinetic profile in patients with rheumatoid arthritis. American College of Rheumatology 2013; San Diego, California, USA: 2013.
    • (2013) American College of Rheumatology , vol.2013
    • Yoo, D.H.1    Park, W.2    Jeka, S.3    Cons Molina, F.4    Hrycaj, P.5    Wiland, P.6
  • 115
    • 85012855515 scopus 로고    scopus 로고
    • The economic implications of biosimilars
    • PID: 26788809
    • Singh SC, Bagnato KM. The economic implications of biosimilars. Am J Manag Care. 2015;21:s331–s40.
    • (2015) Am J Manag Care , vol.21 , pp. s331-s340
    • Singh, S.C.1    Bagnato, K.M.2
  • 116
    • 84893044719 scopus 로고    scopus 로고
    • Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars?
    • COI: 1:CAS:528:DC%2BC2cXisFOlsQ%3D%3D, PID: 24114449
    • Lee H. Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars? AAPS J. 2014;16:22–6. doi:10.1208/s12248-013-9534-y.
    • (2014) AAPS J , vol.16 , pp. 22-26
    • Lee, H.1
  • 118
    • 85021186693 scopus 로고    scopus 로고
    • inVentiv Health Clinical
    • Accessed 10 Mar
    • inVentiv Health Clinical. Elderly representation in clinical trials: not a gray area. http://www.inventivhealthclinical.com/resource-library-white-papers.htm. Accessed 10 Mar 2016.
    • (2016) Elderly representation in clinical trials: not a gray area
  • 119
    • 84864742645 scopus 로고    scopus 로고
    • The challenges of switching medicines, Stockholm Network
    • Chu R, Torstensson D, Pugatch M. Patient safety and comfort. The challenges of switching medicines. Stockholm Network. 2010. http://www.patients-rights.org/uploadimages/Patient_Safety_and_Comfort_The_Challenges_of_Switching.pdf. Accessed 31 Mar 2016.
    • (2010) Patient safety and comfort
    • Chu, R.1    Torstensson, D.2    Pugatch, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.